Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Renin-Angiotensin-Aldosterone System

Aldosterone, Plasma Renin Activity, and Aldosterone/Renin Ratio in a Normotensive Healthy Pediatric Population

Alejandro Martinez-Aguayo, Marlene Aglony, Carmen Campino, Hernan Garcia, Rodrigo Bancalari, Lillian Bolte, Carolina Avalos, Carolina Loureiro, Cristian A. Carvajal, Alejandra Avila, Viviana Perez, Andrea Inostroza, Carlos E. Fardella
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.110.155135
Hypertension. 2010;56:391-396
Originally published August 18, 2010
Alejandro Martinez-Aguayo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marlene Aglony
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Campino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hernan Garcia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodrigo Bancalari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lillian Bolte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Avalos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Loureiro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristian A. Carvajal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandra Avila
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviana Perez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Inostroza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos E. Fardella
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Subjects and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Primary aldosteronism is an important cause of secondary hypertension and is suspected in adults with an aldosterone/renin ratio ≥25. The normal aldosterone/renin ratio is unknown in children. The aim was to establish serum aldosterone, plasma renin activity, and aldosterone/renin ratio values in a healthy pediatric population. A cross-sectional study was performed in 211 healthy normotensive children (4 to 16 years old). Two subgroups of normotensive children were obtained: with hypertensive parents (NH) (n=113) and normotensive parents (n=98). Blood samples for measuring serum aldosterone, plasma renin activity, aldosterone/renin ratio, and DNA were collected. In subjects with aldosterone/renin ratio ≥25, the chimeric CYP11B1/CYP11B2 gene was investigated by long-extension PCR. Results are expressed as median [Q1–Q3]. NH and normotensive parents groups were similar in serum aldosterone (6.5 [3.6 to 9.0] ng/dL versus 6.5 [2.9 to 9.7] ng/dL; P=0.968) and plasma renin activity (2.3 [1.6 to 3.1] versus 2.4 [1.7 to 3.7] ng/mL per hour; P=0.129). The aldosterone/renin ratio was higher in the NH group, but this difference did not reach statistical significance (2.8 [1.9 to 4.1] versus 2.5 [1.4 to 4.0], P=0.104). In one subject of the NH group, the chimeric CYP11B1/CYP11B2 gene was detected. We demonstrated that normal aldosterone/renin ratio values in a healthy pediatric population without NH were lower than those reported for an adult normotensive population.

  • primary aldosteronism
  • plasma renin activity
  • arterial hypertension
  • aldosterone/plasma renin activity ratio

Primary aldosteronism (PA) has been recognized as a cause of hypertension since the 1950s. When the first case was reported, one of the most important characteristics was the presence of a severe hypertensive profile associated with hypokalemia.1 In recent years, the importance of diagnosing PA has become clear for its ability to induce hypertension, as well as the deleterious effects of aldosterone in various organs, including effects on the heart and blood vessels via nonepithelial receptors, independent of changes in blood pressure (BP).2,3

In 1976, Dunn and Espiner4 first suggested simultaneous measurements of serum aldosterone (SA) concentration and plasma renin activity (PRA), as well as the aldosterone/renin ratio (ARR) as a potentially useful screening test for PA. The ARR has been considered a useful tool in screening for PA.5–9 The prevalence of PA increased from <1% when hypokalemia was used for screening to close to 10% when the ARR was used for screening, and this value was even higher in patients with severe or resistant hypertension.10–13 The ARR by itself, however, does not result in a definitive diagnosis of PA. A confirmatory test is necessary, and 30 to 50% of patients with a positive ARR could display aldosterone levels that are normally suppressed after confirmatory testing.14

Today, different groups have established the ARR cut-off in adults to be between 20 to 40 when SA is measured in ng/dL, and PRA is measured in ng/mL per hour.5–7,15,16 However, this value has not been validated in children and adolescents. Data regarding the prevalence of PA and the normal parameters of the renin angiotensin system, especially the ARR, are unknown for pediatric nonhypertensive individuals.

The high prevalence of PA in the general hypertensive population16–18 allows us to postulate that PA may begin in the pediatric population prior to the development of hypertensive and vascular damage. Furthermore, up to 4% of school children are hypertensive,19,20 and the magnitude of the burden of hypertension requires increased awareness, treatment, and control. These considerations argue for greater efforts toward demonstrating any underlying cause of hypertension in order to facilitate early specific treatment that might decrease cardiovascular risk and, in cases confirmed as having a genetic basis, to enable genetic counseling.21

Our objectives were to establish the SA, PRA, and ARR levels in a pediatric normotensive healthy population.

Subjects and Methods

A cross-sectional study was designed. Chilean children and adolescents of both sexes, ranging from 4 to 16 years old, were invited to participate. We recruited patients from lower-middle, middle, and high socioeconomic status. All subjects were evaluated at the pediatric endocrinology and nephrology clinics of the Pontificia Universidad Católica de Chile from July 2009 to March 2010.

Two hundred thirty-eight subjects agreed to participate in the study. A complete physical examination was performed for all of them by 2 pediatric endocrinologists (A.M.-A. and H.G.), 1 pediatric nephrologist (M.A.), and 4 pediatricians with training in pediatric endocrinology (C.A., L.B., R.B., and C.L.). Height was measured using a wall-mounted Harpenden stadiometer (Holtain). Weight and total fat mass percentage were also assessed by bioelectrical impedance (Tanita Corporation of America). Subjects with severe obesity (z score, >2.5) were excluded. Pubertal development was assessed according to the method of Marshall and Tanner.22

Trained nurses measured the BP and heart rate of all of the subjects and their parents. Three measurements were taken consecutively in the right arm at 5-minute intervals, while the patient was in a seated position, using an oscillometric method (Dinamap CARESCAPE V100, GE Healthcare). This was done following the published recommendations23,24 with a cuff and bladder size adjusted to upper-arm girth. The office BP of children and their parents was classified according the Fourth Report of Task Force and JNC 7 (The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) guidelines.23,24 In addition to measuring BP, an adult was considered hypertensive if there was a history of hypertension on treatment. Normotension in children was defined as an average systolic BP (SBP) and/or diastolic BP less than the 90th percentile for gender, age, and height. We calculated the BP index so that we could compare children from different gender, age, and stature percentiles. The BP index was determined using the observed BP/50th percentile BP level for gender, age, and stature using the normal values reported;23 for more details, please see the supplemental data, available online at http://hyper.ahajournals.org. All the subjects with elevated BP were confirmed using the auscultatory method. Children with prehypertension or hypertension were excluded.

We measured serum creatinine (Cr), calcium, urea, glucose, and a hepatic profile (alkaline phosphatase, bilirubin, alanine aminotransferase, aspartate aminotransferase, and albumin) in all subjects. We used this screening to exclude subjects with renal disease, diabetes mellitus, hepatic failure, and hypercalcemia. With the aim of reducing the chances of, to including children with, endogenous hypercortisolism, we excluded those subjects with combined reduced linear growth and increased weight; these elements have quite high sensitivity in identifying subjects at risk of having endogenous hypercortisolism.25

We also excluded children who were undergoing any treatment that might affect the renin-angiotensin system or taking antihypertensive drugs at the time of the diagnosis.

A total of 211 healthy normotensive children were enrolled. Following an overnight fast, basal blood samples were obtained between 8:00 and 10:00 am to measure sodium, potassium, SA, PRA, and ARR (subjects were in the sitting position with at least a 15-minute rest). The blood samples were drawn from an indwelling catheter positioned in an antecubital vein, and they were separated immediately after collection. At the same time, 12-hour nocturnal urine (between 7:00 pm and 7:00 am) samples were collected. Total 12-hour urine volumes were measured, and 50-mL aliquots were stored to measure urinary-free cortisol (UFF), Cr, sodium, and potassium. We also calculated the fractional excretion of sodium. The serum, plasma, and urine samples were stored at −70°C until analysis. Patients without a full sample at the 12-hour urine collection were not included in this analysis.

The protocol was approved by the Ethical Committee of the Faculty of Medicine of the Pontificia Universidad Católica de Chile in accordance with the Helsinki Declaration. All parents signed informed consent forms, and subjects older than 7 years old gave their assent before entering the study.

Hormonal and Biochemical Assays

The results were expressed in SI units according the instructions of the journal. However, for SA, we use ng/dL (and pmol/L in parentheses), and for PRA, we use ng/mL per hour instead of μg/L per hour.

SA was measured by radioimmunoassay using a commercial kit from Diagnostic Products. The intraassay and interassay coefficients of variation were 5.1 and 7.1%, respectively. PRA was determined as previously described by Menard and coworkers.26 The intraassay and interassay coefficients of variation were 6.1 and 8.2%, respectively.27 The lower limit of the PRA assay was 0.1 ng/mL per hour.28 Serum cortisol and UFF were measured by immunoassay in automated equipment (IMMULITE 2000; Siemens Healthcare Diagnosis, Inc). The intraassay coefficients of variation were 6.8 and 8.7%, respectively. Serum and urinary Cr were measured by the Jaffe method in automated equipment (Modular Analytics; Roche). UFF was normalized by Cr (UFF/Cr), and kidney function was estimated using serum Cr levels.

Genetic Study

In subjects with an ARR >25, a genetic study was performed to determine the presence of familial hyperaldosteronism type I (no. 103900; Online Mendelian Inheritance in Man). Genomic DNA was isolated from peripheral blood leukocytes and purified by a commercial kit (Qiagen). The genetic study was carried out by long-extension PCR of the chimeric gene CYP11B1/CYP11B2 using a protocol previously described by Jonsson et al29 and modified by MacConnachie et al.30

Data Analysis

Two subgroups of subjects were defined according to the BP of their parents: normotensive children with hypertensive parents (NH) and normotensive children with normotensive parents (NN). Results were expressed as median values (interquartile range, [Q1–Q3]).

Statistical analyses were performed using the SPSS 15.0 program for Windows (SPSS, Inc). The comparison between NH and NN groups was performed using the Mann–Whitney U test. The measurements of SA, PRA, and ARR were logarithmically transformed to achieve a normal distribution before Pearson association analysis. We also performed partial correlation analysis to find the association between 2 variables after removing the effects of other variables.

Correlations involving the Tanner pubertal state were performed using Spearman’s correlation, and probability values <0.05 were considered as statistically significant.

Results

Of the 211 normotensive children selected to participate in this study, 113 children had at least 1 hypertensive parents (NH group), and 98 children had normotensive parents (NN group). In the NH group, 60.2% of the parents were receiving treatment: 41% with angiotensin-converting enzyme inhibitors, 28% with angiotensin II receptor blockers, 20% with β blockers, 13% with diuretics, and 8% with calcium channel blockers. In some cases, combination therapy was prescribed. Clinical and biochemical characteristics of the total group, as well as the subgroups, are shown in Table 1.

View this table:
  • View inline
  • View popup

Table 1. Clinical and Biochemical Characteristics of Children Stratified by Parental BP Status

Clinical Characteristics

The subjects’ distributions by gender, age, height, body mass index, and percentage of body fat were similar between the NH and NN groups (Table 1). The diastolic BP index was also similar between both groups. However, the SBP index was higher in the NH group than the NN group (Table 1).

Biochemical Characteristics

The values of SA, PRA, ARR, serum cortisol, serum Cr, serum potassium, serum sodium, nocturnal UFF/Cr, and fractional excretion of sodium did not show any differences between the group of children with NH and the group of children with NN (Table 1). Moreover, when PRA data were analyzed according to their distribution in percentiles, we observed that PRA at the 95th and 97th percentiles was lower in the NH group than the NN group (4.9 and 6.8 ng/mL per hour versus 7.4 and 10.6 ng/mL per hour, respectively). As a consequence, the ARR at the 95th and 97th percentiles tended to be higher in the NH group (8.9 and 15.0, respectively) than the NN group (9.1 and 13.5, respectively) (Table 2).

View this table:
  • View inline
  • View popup

Table 2. Serum Aldosterone, Plasma Renin Activity, and ARR in the Total Group and in the Subgroups Stratified by Parental BP Status

The examination of the results by gender showed differences in PRA but not in SA or ARR. In the total group, median levels of SA were similar in males and females, 7.0 (3.6 to 10.2) ng/dL (194.2 [99.8 to 282.9] pmol/L) versus 6.0 (3.2 to 8.9) ng/dL (166.5 [88.8 to 246.9] pmol/L), P=0.160. The same result was observed in the NH group, 6.6 (4.0 to 10.1) ng/dL (183 [110 to 280] pmol/L) versus 6.1 (3.3 to 8.9) ng/dL (167.8 [91.6 to 247.6] pmol/L), P=0.400; and the NN group, 7.5 (3.0 to 11.3) ng/dL (208 [83 to 313] pmol/L) versus 6.0 (3.1 to 8.8) ng/dL (166.5 [86 to 244] pmol/L), P=0.247.

The levels of PRA, however, showed differences in the total group. Males had higher PRA levels than females (2.5 [1.7 to 3.5] ng/mL per hour versus 2.1 [1.3 to 3.1] ng/mL per hour; P=0.024). This same pattern was also observed in the NH group (2.6 [1.9 to 3.3] ng/mL per hour versus 1.9 [1.1 to 3.0] ng/mL per hour; P=0.005) but not in the NN group (2.5 [1.7 to 3.8] ng/mL per hour versus 2.4 [1.8 to 3.6] ng/mL per hour; P=0.749).

The above differences were not reflected in ARR. In the total group, ARR was similar in males and females (2.6 [1.6 to 4.3] versus 2.7 [1.8 to 3.9]; P=0.646). The same fact was observed in the NH group (2.4 [1.8 to 4.1] versus 3.1 [2.1 to 4.2]; P=0.094), as well as the NN group (2.7 [1.5 to 4.4] versus 2.4 [1.3 to 3.6]; P=0.337).

Correlations Between Serum Aldosterone, Plasma Renin Activity, and SA/PRA Ratio with Age

Median values of SA, PRA and ARR stratified by age are showed in Figure.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure. Boxplot of log SA, log PRA, and log aldosterone/PRA ratio grouped by age. The gray box represents normotensive subjects with hypertensive parents (NH group). The white box represents normotensive subjects with normotensive parents (NN group). The top of the box represents the 75th percentile, the bottom of the box represents the 25th percentile, and the line in the middle represents the 50th percentile. The whiskers (the lines that extend out the top and bottom of the box) represent the highest and lowest values that are not outliers or extreme values. Outliers (values that are between 1.5 and 3 times the interquartile range) are represented by circles beyond the whiskers, and extreme values are represented by stars (values that are more than 3 times the interquartile range).

SA was inversely correlated with age in the total group (r=−0.176; P=0.01) and the NN group (r=−0.2; P=0.047) but not in the NH group (r=0.096; P=0.096). PRA was inversely correlated with age in the total group (r=−0.285; P=0.001), as well as the NH and NN groups (r=−0.191; P=0.043 and r=−0.374, P<0.001, respectively). The ARR values did not correlate with age (P=0.153). For other association results, please see the supplemental data.

Genetic Study

Only 1 of the 211 subjects studied had an ARR >25. This girl was in the NH group and had an ARR of 82. Genetic analysis confirmed the chimeric gene CYP11B1/CYP11B2.

Discussion

This study demonstrates that the ARR in a healthy normotensive pediatric population is lower than that reported in an adult population. This suggests that PA screening in children should be done with a significantly lower cut-off value for ARR than that reported in an adult population to avoid missing patients affected by this condition.

In our study, the mean ARR in healthy normotensive children with normotensive parents was under half of the ARR reported by our group in normotensive subjects from an adult Chilean population (ARR, 9.06±7.48).16 Moreover, the group without hypertensive parents tended to have lower values of ARR than the group with hypertensive parents, which suggests that prehypertensive conditions in these children begin at an early age. Two facts support this hypothesis: (1) although the 2 groups of subjects were normotensive, the group of children with NH had a higher SBP index than those with NN, and (2) we found a healthy normotensive child in the NH group with chimeric gene (CYP11B1/CYP11B2).

The pathophysiology of hypertension is not completely known, and genetic influences have been attributed in ≈30 to 60% of cases.31,32 In addition, a positive family history represents a major risk factor for future hypertension in nonhypertensive offspring,33 and the parental hypertensive antecedent predicts changes in offspring SBP during follow-up.34 Considering that the NH group probably represents subjects with prehypertensive conditions, we choose the group of children without hypertensive parents to calculate our normal ARR reference values in the pediatric population. Alvarez-Madrazo et al35 found that the ARR is influenced by genetic and environmental factors, and the ethnic background of the population studied should be considered. Our Chilean population is composed of 30% Hispanic-white, 65% “white mestizo,” and 5% Amerindian.36 Other studies using other populations with different ethnicities should be performed to establish relevant specific reference ranges for ARR.

Age-related changes in the renin-aldosterone system in normal humans are well documented. The most pronounced changes are observed at the extremes of life.37 We found a negative correlation between age and PRA. Similar results were previously described by Wilson et al,38 who reported that PRA and active renin concentrations were negatively correlated with age. Moreover, Fiselier et al39 measured basal PRA, as well as active and inactive plasma renin concentrations, in 89 healthy recumbent children aged between 1 week and 16 years and found an age-related decrease for active, inactive, and total renin concentrations. In relation to aldosterone, our results are similar with other reports that demonstrated decreased aldosterone levels with age.40 However, aldosterone did not reach a significant association with age in the NH group, which was likely due to familial antecedents of hypertension or other factors that could influence the aldosterone levels. Although a trend toward a positive correlation was demonstrated in the NN group, the correlation between age and ARR did not reach statistical significance. It is likely that the narrow age range (4 to 16 years) and the number of patients was not enough to demonstrate a significant association. The BP was not significantly associated to ARR in our study, which was similar to previous findings by Li et al.41

The percentage of body-fat mass was inversely associated with aldosterone and PRA (see supplemental data). However, this was not observed with body mass index. When the percentage of body-fat mass was controlled by age, the correlation was lost. These results suggest that changes in the body composition were not an important determinant in the aldosterone or renin levels during childhood.

If we consider the age of the children enrolled in this study, it is probable that their parents were relatively young and some children with hypertensive parents could have a greater risk of heritable hypertension. However, some normotensive parents could also become hypertensive in the future. For this reason, the subdivision of the children according to the presence or absence of hypertensive parents should be taken with caution. Finally, given the fact that ARR showed a continuous increase with age within the population studied, having 1 cut-off for children and another for adults could be an oversimplification, and the ideal would be to create age-related percentile charts. However, to achieve this, we would need a larger group of normal subjects. Moreover, because many factors may play roles in ARR levels, such as ethnicity, assay methods, and environmental factors, it is necessary that each center have validated normal data for ARR. Children with a high ARR should undergo a confirmatory test to definitively confirm or exclude the diagnosis of PA. Four testing procedures (oral sodium loading, saline infusion, fludrocortisone suppression, and captopril challenge) are in common use in adults.15 However, a validated confirmatory test in children has not been reported in the current literature.

Perspectives

ARR values appear to be lower in children. This should be taken into account when screening pediatric populations for PA.

More studies will be necessary to validate our proposed cut-off and to determine its capacity to predict the risk of PA. Our data have contributed to knowledge of renin and aldosterone levels during childhood and should help in the development of guidelines for detection of PA as a cause of hypertension.

Acknowledgments

We thank Dr John C. Achermann for his critical review of this manuscript. We also thank our patients and their families.

Sources of Funding

This work was supported by the Chilean Grant FONDECYT 1100356 and 1070876. A.M.-A. is the recipient of grants from Becas-Chile and from the Pontificia Universidad Católica de Chile. C.A.C. is fellow of Comision Nacional de Investigacion Cientifica y Tecnologica de Chile.

Disclosures

None.

Footnotes

  • M.A. and A.M.-A. contributed equally to this work.

  • Received April 19, 2010.
  • Revision received May 8, 2010.
  • Accepted July 12, 2010.

References

  1. ↵
    Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable “essential” hypertension. JAMA. 1965; 193: 200–206.
    OpenUrlCrossRefPubMed
  2. ↵
    Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45: 1243–1248.
    OpenUrlCrossRefPubMed
  3. ↵
    Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008; 29: 133–154.
    OpenUrlCrossRefPubMed
  4. ↵
    Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Aust NZ J Med. 1976; 6: 131–135.
    OpenUrlCrossRefPubMed
  5. ↵
    McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab. 1991; 73: 952–957.
    OpenUrlCrossRefPubMed
  6. ↵
    Gordon R. Mineralocorticoid hypertension. Lancet. 1994; 344: 240–243.
    OpenUrlCrossRefPubMed
  7. ↵
    Lins PE, Adamson U. Plasma aldosterone-plasma renin activity ratio: a simple test for primary aldosteronism. Acta Endocrinol. 1986; 113: 564–569.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Stowasser M, Gordon RD. The aldosterone-renin ratio for screening for primary aldosteronism. Endocrinologist. 2004; 14: 267–276.
    OpenUrlCrossRef
  9. ↵
    Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005; 90: 72–78.
    OpenUrlCrossRefPubMed
  10. ↵
    Seiler L, Rump LC, Schulte-Mönting J, Slawik M, Borm K, Pavenstädt H, Beuschlein F, Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol. 2004; 150: 329–337.
    OpenUrlAbstract
  11. ↵
    Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004; 89: 1045–1050.
    OpenUrlCrossRefPubMed
  12. ↵
    Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension. 2003; 42: 161–165.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002; 40: 892–896.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab. 2005; 16: 114–119.
    OpenUrlCrossRefPubMed
  15. ↵
    Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr., Montori VM. The Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93: 3266–3281.
    OpenUrlCrossRefPubMed
  16. ↵
    Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000; 85: 1863–1867.
    OpenUrlCrossRefPubMed
  17. ↵
    Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the tayside hypertension clinic population. J Hum Hypertens. 2000; 14: 311–315.
    OpenUrlCrossRefPubMed
  18. ↵
    Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res. 2007; 30: 111–117.
    OpenUrlCrossRefPubMed
  19. ↵
    Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004; 113: 475–482.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007; 298: 874–879.
    OpenUrlCrossRefPubMed
  21. ↵
    Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wühl E, Zanchetti A. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009; 27: 1719–1742.
    OpenUrlCrossRefPubMed
  22. ↵
    Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969; 44: 291–303.
    OpenUrlFREE Full Text
  23. ↵
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114: 555–576.
    OpenUrlCrossRefPubMed
  24. ↵
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Hypertension. 2003; 42: 1206–1252.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Batista DL, Riar J, Keil M, Stratakis CA. Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics. 2007; 120: e575–e586.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Kreft C, Menard J, Corvol P. Value of renin measurement, saralasin test, and acelretolol treatment in hypertension. Kidney Int. 1979; 15: 176–183.
    OpenUrlPubMed
  27. ↵
    Sealey JE, James GD, Laragh JH. Interpretation and guidelines for the use of plasma and urine aldosterone and plasma angiotensin II, angiotensinogen, prorenin, peripheral, and renal vein renin tests. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995: 1953–1968.
  28. ↵
    Montero J, Soto J, Fardella C, Foradori A, Valdés G. Medición de la actividad de renina plasmática a niveles bajos. Optimización del método. Rev Med Chil. 1998; 126: 151–154.
    OpenUrlPubMed
  29. ↵
    Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun. 1995; 207: 565–571.
    OpenUrlCrossRefPubMed
  30. ↵
    MacConnachie AA, Kelly KF, McNamara A, Loughlin S, Gates LJ, Inglis GC, Jamieson A, Connell JM, Haites NE. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab. 1998; 83: 4328–4331.
    OpenUrlCrossRefPubMed
  31. ↵
    Hottega JJ, Boomsma DI, Kupper N, Posthuma D, Snieder H, Willemsen G, de Geus EJ. Heritability and stability of resting blood pressure. Twin Res Hum Genet. 2005; 8: 499–508.
    OpenUrlCrossRefPubMed
  32. ↵
    Levy D, DeStefano AL, Larson MG, O‘Donnell CJ, Lifton Rp, Gavras H, Cupples LA, Myers RH. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotype in subjects from the Framingham heart study. Hypertension. 2000; 36: 477–483.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Family (parental) history and prevalence of hypertension. Results of a nationwide screening program. JAMA. 1979; 241: 43–46.
    OpenUrlCrossRefPubMed
  34. ↵
    Lieb W, Pencina MJ, Wang TJ, Larson MG, Lanier KJ, Benjamin EJ, Levy D, Tofler GH, Meigs JB, Newton-Ched Ch, Vasan RS. Association of parental hypertension with concentration of select biomarkers in nonhypertensive offspring. Hypertension. 2008; 52: 381–386.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Alvarez-Madrazo S, Padmanabhan S, Mayosi BM, Watkins H, Avery P, Wallace AM, Fraser R, Davies E, Keavney B, Connell JM. Familial and phenotypic associations of the aldosterone Renin ratio. J Clin Endocrinol Metab. 2009; 94: 4324–4333.
    OpenUrlCrossRefPubMed
  36. ↵
    Medina E, Kaempffer AM. Elementos de Salud Pública. Biblioteca Digital de la Universidad de Chile. Available at http://mazinger.sisib.uchile.cl/repositorio/lb/ciencias_quimicas_y_farmaceuticas/medinae/cap2/5b6.html. Accessed 22 March, 2010.
  37. ↵
    Bauer JH. Age-related changes in the renin-aldosterone system. Physiological effects and clinical implications. Drugs Aging. 1993; 3: 238–245.
    OpenUrlPubMed
  38. ↵
    Wilson DM, Stevenson DK, Luetscher JA. Plasma prorenin and renin in childhood and adolescence. Am J Dis Child. 1988; 142: 1070–1072.
    OpenUrlCrossRefPubMed
  39. ↵
    Fiselier T, Derkx F, Monnens L, Van Munster P, Peer P, Schalekamp M. The basal levels of active and inactive plasma renin concentration in infancy and childhood. Clin Sci. 1984; 67: 383–387.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Dillon MJ, Ryness JM. Plasma renin activity and aldosterone concentration in children. BMJ. 1975; 4: 316–319.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Li R, Richey PA, DiSessa TG, Alpert BS, Jones DP. Blood aldosterone-to-renin ratio, ambulatory blood pressure, and left ventricular mass in children. J Pediatr. 2009; 155: 170–175.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
September 2010, Volume 56, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Subjects and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Aldosterone, Plasma Renin Activity, and Aldosterone/Renin Ratio in a Normotensive Healthy Pediatric Population
    Alejandro Martinez-Aguayo, Marlene Aglony, Carmen Campino, Hernan Garcia, Rodrigo Bancalari, Lillian Bolte, Carolina Avalos, Carolina Loureiro, Cristian A. Carvajal, Alejandra Avila, Viviana Perez, Andrea Inostroza and Carlos E. Fardella
    Hypertension. 2010;56:391-396, originally published August 18, 2010
    https://doi.org/10.1161/HYPERTENSIONAHA.110.155135

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Aldosterone, Plasma Renin Activity, and Aldosterone/Renin Ratio in a Normotensive Healthy Pediatric Population
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Aldosterone, Plasma Renin Activity, and Aldosterone/Renin Ratio in a Normotensive Healthy Pediatric Population
    Alejandro Martinez-Aguayo, Marlene Aglony, Carmen Campino, Hernan Garcia, Rodrigo Bancalari, Lillian Bolte, Carolina Avalos, Carolina Loureiro, Cristian A. Carvajal, Alejandra Avila, Viviana Perez, Andrea Inostroza and Carlos E. Fardella
    Hypertension. 2010;56:391-396, originally published August 18, 2010
    https://doi.org/10.1161/HYPERTENSIONAHA.110.155135
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Etiology
  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Epidemiology, Lifestyle, and Prevention
    • Epidemiology
  • Imaging and Diagnostic Testing
    • Diagnostic Testing

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured